Activation of AMP-activated protein kinase (AMPK) in endothelial cells regulates energy homeostasis, stress protection and angiogenesis, but the underlying mechanisms are incompletely understood. Using a label-free phosphoproteomic analysis, we identified glutamine:fructose-6-phosphate amidotransferase 1 (GFAT1) as an AMPK substrate. GFAT1 is the rate-limiting enzyme in the hexosamine biosynthesis pathway (HBP) and as such controls the modification of proteins by O-linked -N-acetylglucosamine (OGlcNAc). In the present study, we tested the hypothesis that AMPK controls O-GlcNAc levels and function of endothelial cells via GFAT1 phosphorylation using biochemical, pharmacological, genetic and in vitro angiogenesis approaches. Activation of AMPK in primary human endothelial cells by 5-aminoimidazole-4-carboxamide riboside (AICAR) or by vascular endothelial growth factor (VEGF) led to GFAT1 phosphorylation at serine 243. This effect was not seen when AMPK was downregulated by siRNA. Upon AMPK activation, diminished GFAT activity and reduced OGlcNAc levels were observed in endothelial cells containing wild-type (WT)-GFAT1 but not in cells expressing nonphosphorylatable S243A-GFAT1. Pharmacological inhibition or siRNAmediated downregulation of GFAT1 potentiated VEGF-induced sprouting indicating that GFAT1 acts as negative regulator of angiogenesis. In cells expressing S243A-GFAT1, VEGFinduced sprouting was reduced suggesting that VEGF relieves the inhibitory action of GFAT1/HBP on angiogenesis via AMPK-mediated GFAT1 phosphorylation. Activation of GFAT1/HBP by high glucose led to impairment of vascular sprouting, while GFAT1 inhibition improved sprouting even if glucose level was high. Our findings provide novel mechanistic insights into the role of HBP in angiogenesis. They suggest that targeting AMPK in endothelium might help to ameliorate hyperglycaemia-induced vascular dysfunction associated with metabolic disorders. Short title: GFAT1 mediates pro-angiogenic AMPK effects
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Introduction
AMPK is an important component of signalling mechanisms regulating energy and nutrient metabolism. It is a heterotrimeric serine/threonine protein kinase consisting of catalytic and regulatory and subunits, each existing as several isoforms [1] . Energy-depriving stresses or pharmacological agents, which increase AMP/ATP and ADP/ATP ratios, trigger binding of AMP to the subunit and activate AMPK via a triple mechanism: (i) allosteric activation, (ii) phosphorylation of threonine 172 on the activation loop of AMPK and (iii) inhibition of dephosphorylation of threonine 172 [2] [3] [4] . The upstream kinases of AMPK include LKB1 in response to metabolic stress and Ca 2+ /calmodulin-dependent protein kinase kinase 2 in response to Ca 2+ -elevating agonists (reviewed in [1] ). AMPK maintains cellular ATP homeostasis by activating ATP-producing pathways and by inhibiting ATP-consuming pathways via phosphorylation of target proteins such as acetyl-CoA carboxylase isoforms 1 and 2, which regulate fatty acid synthesis and oxidation, respectively [5, 6] . Furthermore, it serves as a metabolic checkpoint for cell growth by inhibiting mammalian target-of-rapamycin complex-1 [7, 8] .
AMPK plays an important role in endothelial cells. It is activated by a variety of stimuli including shear stress, oxidants, hormones, vascular mediators and VEGF (reviewed in [9] ).
Activation of AMPK in endothelial cells seems to be associated with regulation of energy supply, stress protection, maintenance of anti-inflammatory and anti-atherogenic phenotypes and regulation of angiogenesis [10] but the underlying mechanisms are not fully elucidated. To further understand cellular functions of AMPK, the identification and characterisation of novel AMPK substrates is therefore of high importance.
Recent studies suggested GFAT1 as a new AMPK target while GFAT2, predominantly expressed in the central nervous system [11], was not found in screens for novel AMPK substrates [12] [13] [14] . GFAT1 is ubiquitously expressed and catalyses the formation of glucosamine-6-phosphate, the first product of the HBP, using fructose-6-phosphate and L-glutamine as substrates. This step is rate-limiting for the synthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), the end product of the HBP. UDP-GlcNAc is used as donor for adding Nacetylglucosamine to serine/threonine residues of proteins. This post-translational modification known as O-GlcNAcylation modulates key biological processes such as transcription, signal transduction and cytoskeletal reorganisation [15] . GFAT is activated by high extracellular glucose, and studies using genetically modified mice demonstrated a causative link between GFAT1 activity and diabetic state [16] [17] [18] . Moreover, GFAT1 activity was shown to be elevated in diabetic patients [19] . The increase in O-GlcNAcylation of proteins as a consequence of GFAT activation is thought to contribute to the development of insulin resistance [20] and endothelial dysfunction [21] , which is an initial event in atherogenesis and a hallmark of vascular complications of type 2 diabetes.
Despite the importance of the HBP in providing the substrate for O-GlcNAcylation, the posttranslational regulation of the key enzyme GFAT is incompletely understood. GFAT1 has been reported to be an AMPK substrate with serine 243 as putative phosphorylation site, which was shown to be activating in vitro [13] , but inhibitory in certain cellular context [12] . However, detailed biochemical characterisation of AMPK-dependent GFAT1 phosphorylation and the functional role of this pathway in physiologically relevant systems have not been established.
Therefore, in the present study we address the role of GFAT1 regulation by AMPK in primary human endothelial cells. We demonstrate that GFAT1 is a component of the VEGF-AMPK pathway in endothelial cells and, as such, a mediator of pro-angiogenic effects of AMPK. Via GFAT1 phosphorylation, AMPK can decrease O-GlcNAcylation of proteins, which may also contribute to beneficial metabolic outcomes of AMPK activation, thus further underlining the importance of AMPK as a drug target.
Experimental procedures

Materials
Cell culture media and sera were from Lonza. Endothelial mitogen was from Hycultec GmbH. Blotting Detection kit were from GE Healthcare. Titansphere 5 m loose beads were from Hichrom Limited. SAINT-RED was from Synvolux Therapeutics B.V. Unless otherwise indicated all other reagents were from Sigma-Aldrich.
Antibodies
Total AMPK (#2532), phospho-AMPK (#2531), total ACC (#3676), phospho-ACC (#3661), and -actin (#4970) antibodies were from Cell Signalling Technology. O-GlcNAc antibody (CTD110.6 clone, #MMS-248R) was from Biolegend Covance. GFAT1 rabbit antiserum was generated as described previously [23] . 
Oligos
The primers used for site-directed mutagenesis of GFAT1 were:
The siRNA duplex oligonucleotides used in this study were based on the human cDNAs encoding AMPK 1, AMPK 2, and GFAT1. AMPK 1-and AMPK 2-specific SMARTpool siRNA reagents (M-005027-02-0020 and M-005361-02-0020, respectively) were purchased from Dharmacon (GE Healthcare). For GFAT1, 5 -GGAGGAUACUGAGACCAUU-3 (sense) and 3 -CCUCCUAUGACUCUGGUAA-5 (anti-sense) siRNA duplex oligonucleotides, reported by Jokela et al. [24] , were obtained from Sigma. A nonspecific control SMARTpool siRNA (D-001810-10-20) was from Dharmacon. 
Mouse embryonic fibroblasts
, where X is any amino acid [7] . Matched peptides were relatively quantified using the height of the extracted ion chromatogram, which was compared between A-769662- 
Cloning, site directed-mutagenesis
Human GFAT1 (NCBI BC045641) was amplified from IMAGE EST 5298728 using KOD Hot Start Polymerase, cloned into pSC-b and sequenced to completion. The resulting plasmid was digested with BamH1 and Not1 and cloned between the same sites into vectors for bacterial (pGEX6P-1) and mammalian (pEBG6P) expression, encoding proteins with an N-terminal glutathione S-transferase (GST) tag. Site-directed mutagenesis was performed by the Stratagene Quickchange method but using KOD Hot Start DNA Polymerase.
For generation of lentiviral particles, cDNA sequences encoding WT-and S243A-GFAT1 were cut off respective pEBG6P vectors using BamH1 and Not1 and inserted between the same sites into pCDH-CMV-MCS-EF1-Puro lentivectors (CD510B-1, System Biosciences (SBI)) to generate pCDH-CMV-MCS-EF1-Puro-GFAT1 and pCDH-CMV-MCS-EF1-Puro-S243A-GFAT1 plasmids for expression of untagged versions of either protein.
In vitro phosphorylation of recombinant GFAT1
WT or S243A mutant of human GST-tagged-GFAT1 were expressed in E. coli and purified using glutathione sepharose resin. Each recombinant protein (1 µg) was treated with 5 U/ml of activated recombinant AMPK trimeric complex ( 2 2 1 Healthcare; 1,000-2,000 cpm/pmol in analytical kinase assays, approx. 10,000 cpm/pmol for phosphorylation site analysis). Reaction was stopped by boiling samples for 5 min in LDS sample loading buffer. The proteins were subjected to electrophoresis on polyacrylamide gels followed by Colloidal Blue staining. GFAT1, which was evident as a 110 kDa band after staining and autoradiography, was excised, and the amount of 32 P incorporation was determined by Cerenkov counting. The stoichiometry of GFAT1 phosphorylation at serine 243 site was estimated based on the following calculations: [ -32 P]ATP had a specific activity of 10,000 cpm/pmol. Since fusion GST-GFAT1 protein weights 104 kDa, 1 µg of this protein used for the kinase assay, corresponded to 9.6 pmol (1x10 -6 /104,000=9.6x10 -12 mol). After a kinase assay and SDS-PAGE, the GFAT band excised from the gel showed a radioactivity count of 32,000 cpm, meaning that 3.2 pmol (32,000/10,000) of phosphate was transferred to the 9.6 pmol of GFAT protein, i. e. 33% of GFAT protein copies were phosphorylated after 5 min of kinase assay.
For phosphosite mapping, the protein was reduced with 10 mmol/l DTT, alkylated with iodoacetamide (50 mmol/l in 0.1 mol/l ammonium bicarbonate) and digested with trypsin (5 g/ml protease in 25 mmol/l triethylammonium bicarbonate). The resulting peptides were applied to a Vydac 218TP215 C18 column equilibrated with 0.1% trifluoroacetic acid (TFA) and the column was developed with a linear gradient of acetonitrile/0.1% TFA at a flow rate of 0.2 ml/min with 0.1 ml fractions collected. 32 P radioactivity was recorded with an on-line monitor.
Identification of phosphorylated peptides present in the radioactive fraction was performed by mass spectrometry.
Primary endothelial cell culture and treatment conditions
Human umbilical vein endothelial cells (HUVEC) were isolated from anonymously acquired umbilical cords according to the Declaration of Helsinki "Ethical principles for Medical
Research Involving Human Subjects" (1964). The study was approved by the Jena University
Hospital ethics committee (no. 3950-12/13). The donors were informed and gave written consent.
The study comprises data obtained in approximately 50 different HUVEC batches (3) (4) (5) individual batches per experimental setting). In general, cells of the first or second passage were used, for experiments with genetic modification first to third passage cells were included.
HUVEC were prepared and cultured in M199 containing 17.5 % fetal calf serum (FCS), 2.5% human serum, and 7.5 µg/ml endothelial mitogen as described previously [27] . Prior to stimulation, HUVEC were serum-starved in M199 containing 0.25% human serum albumin (HSA) for 4 h. Subsequently, 2 mmol/l AICAR or vehicle was added for 1 h if not specified. 
GFAT enzymatic activity assay
Endothelial cells were lysed as described in the previous chapter except that 2 mM DTT and 1 mM fructose-6-phosphate were included into the lysis buffer to stabilise the enzyme [31] . To separate GFAT from other glutaminases present in the cell lysate, GFAT was immunopurified as detailed above and the activity of GFAT was determined employing a spectrophotometric assay, in which glutaminase activity of GFAT is coupled to the glutamate dehydrogenase reaction [32] .
Briefly, GFAT immunoprecipitates were resuspended in 100 l assay mixture consisting of 6 mmol/l fructose-6-phosphate, 10 mmol/l glutamine (saturating concentrations for both substrates), 0.3 mmol/l 3-acetylpyridine adenine dinucleotide (APAD), 50 mmol/l KCl, 100 mmol/l KH 2 PO 4 , (pH 7.5), 1 mmol/l EDTA, and 6 U of glutamate dehydrogenase. The assay was incubated at 37°C for 2 h with agitation and stopped by centrifugation at 13,000 x g for 1 min to separate the protein G sepharose-bound enzyme from the substrates. Afterwards, the absorbance of supernatants due to reduction of APAD to APADH was monitored spectrophotometrically at 365 nm. A standard curve was prepared using 0 -25 nmol glutamate [33] . A unit of activity was defined as 1 nmol of glutamate formed per min. The remaining beads were used to control for GFAT equality and phosphorylation level in every sample.
Immunoblotting
Cell lysates ( Antibody dilutions were prepared in TBST containing 5% BSA, 5% milk for total and phospho- 
Genetic manipulations of HUVEC
The RNA interference (RNAi) duplex oligos against AMPK 1, AMPK 2, GFAT1 and nontargeting control-siRNA were transfected into HUVEC for 72-120 h using the amphiphilic delivery system SAINT-RED as described previously [33] .
For expression of WT-GFAT1 and S243A-GFAT1, HUVEC were transduced using freshly prepared lentiviral particles and stable transductants were puromycin-selected. For more detailed description of the procedure, see Supplementary Material, Methods.
Spheroid assay
Spheroids were generated by mixing cells suspended in M199 growth medium (untreated 
GFAT1 is phosphorylated by AMPK at serine 243
Mass spectrometry analysis identified a GFAT1 phosphopeptide containing serine 243 within the sequence, which perfectly complies with the AMPK consensus motif ( Figure 1A Figure 2A) . Importantly, when the activity of endogenous GFAT1 immunopurified from AICAR-stimulated endothelial cells was measured, a considerable decrease was observed indicating that AMPK-mediated GFAT phosphorylation has an inhibitory impact on enzyme activity ( Figure 2D ). Controls proving that the measured activity is attributed to GFAT are shown in Supplementary Figure S3 .
Based on the results obtained with AICAR, we hypothesised that VEGF, which had been shown to trigger AMPK activation in endothelial cells [10] , may affect GFAT1 as well. Indeed, phosphorylation of GFAT1 was increased in response to VEGF at time points (5-10 min) at which AMPK was activated ( Figure 2E ). This increase was prevented when both AMPK 1 and AMPK 2 were silenced ( Figure 2F, G) proving that VEGF-induced GFAT1 phosphorylation was AMPK-dependent. GFAT1 phosphorylation was maintained up to 1 h after VEGF treatment (Supplementary Figure S4) indicating prolonged VEGF effects on HBP activity via AMPK.
Together, these data demonstrate for the first time that endogenous GFAT1 is a physiological AMPK substrate in human endothelial cells and is a component of the VEGF-AMPK signaling pathway.
Serine 243 of GFAT1 is responsible for AMPK effects on HBP in endothelial cells
To understand the functional significance of the AMPK-GFAT1 signalling axis, we compared OGlcNAc levels in HUVEC with modulated AMPK expression or activity. Protein O-GlcNAcylation was increased in AMPK 1/ 2-depleted HUVEC (21% increase against control cells) ( Figure 3A, B) , and, in contrast, decreased in HUVEC stimulated with AICAR (56% reduction against untreated cells) ( Figure 3C, D) .
In order to check whether inhibition of O-GlcNAcylation by AMPK is mediated via GFAT1 phosphorylation, we generated HUVEC stably expressing WT-GFAT1 or the S243A mutant (WT-HUVEC or S243A-HUVEC, respectively). GFAT1 protein levels were increased to a comparable extent and in a physiological range in both types of transductants (up to two-fold) ( Figure 3E, F) . Keeping transgene expression at these moderate levels preserves physiological GFAT1/AMPK ratios thus allowing studying AMPK-dependent regulation of GFAT1 and modulation of O-GlcNAc levels via AMPK-GFAT1 signalling. At this modest transgene expression, basal O-GlcNAc levels were not altered in WT-or S243A-HUVEC compared to control cells transduced using empty lentiviral vector. This is in line with a previous report
showing that 2.6-fold stable overexpression of GFAT1 in NIH-3T3 fibroblasts does not increase UDP-GlcNAc levels robustly at longer culture time, possibly due to feedback mechanisms limiting GFAT1 activity [34] .
AMPK stimulation of the generated HUVEC lines with AICAR led to a significant increase of phospho-GFAT1 in control cells and WT-HUVEC but only to a marginal alteration in S243A-HUVEC ( Figure 3E and G) due to residual endogenous GFAT1. Consequently, the inhibitory effect of AICAR on protein O-GlcNAcylation was clearly seen in control and WT-HUVEC, while it was low in HUVEC expressing S243A-GFAT1 ( Figure 3E and H) . In addition, a reduced inhibitory effect of AMPK on O-GlcNAc levels was observed in HEK293 cells expressing S243A-GFAT1 (Supplementary Figure S5) .
Taken together, these data underline the importance of serine 243 as a target for AMPK and a mediator of AMPK effects on HBP in endothelial cells.
GFAT1 controls angiogenesis
Our group had demonstrated that AMPK 1 activated by VEGF mediates in vitro and in vivo angiogenesis [10] . Since GFAT1/HBP was now identified as a component of the VEGF-AMPK pathway in endothelial cells, we investigated whether it was involved in the regulation of VEGFinduced angiogenesis.
We first used the glutamine analogue DON as GFAT1 antagonist and studied its effect on angiogenesis employing a spheroid assay. Figure 4A Since DON also inhibits other glutamine-utilizing enzymes, we secondly applied a genetic approach to modulate GFAT1. We treated HUVEC with GFAT1-specific siRNA, which led to a significant downregulation of GFAT1 expression ( Figure 5A, B) . Together, these data demonstrate that VEGF-induced angiogenesis is inhibited by GFAT1/HBP.
GFAT1 phosphorylation at serine 243 mediates VEGF-induced pro-angiogenic effects of AMPK
The above described data indicate that VEGF via activation of AMPK and subsequent phosphorylation of GFAT may impair the HBP and thus relieve its inhibitory action on angiogenesis. In order to provide a proof for this, we compared VEGF-induced angiogenesis in WT-HUVEC and S243A-HUVEC. VEGF triggered a 5.4-and 5.1-fold increase of sprout number per spheroid in control and WT-HUVEC, respectively, while it caused only a 3-fold increase in S243A-HUVEC over basal levels ( Figure 6A, B) , meaning 40% reduction of VEGFeffect in S243A-HUVEC compared to WT-HUVEC ( Figure 6A and C).
The differences in VEGF-induced angiogenesis seen between control or WT-HUVEC and SA-HUVEC correlate with the presence and absence of O-GlcNAcylation regulation by AMPK observed in these cells, respectively ( Figure 3E and H) . Thus, the reduced sprouting in S243A-HUVEC can be attributed to the impaired regulation of GFAT1/HBP by the VEGF-AMPK pathway. These data provide unequivocal evidence that GFAT1 phosphorylation at serine 243 represents one of the mechanisms underlying pro-angiogenic effects of AMPK in response to VEGF.
Discussion
An increase of the glucose flux through HBP and chronically elevated O-GlcNAcylation of target proteins is increasingly recognised as an important contributor to the pathogenesis of type 2 diabetes and its cardiovascular complications [35] . However, the regulation of the HBP and the mechanisms and functions of protein O-GlcNAcylation are poorly characterised. The present study reveals that AMPK, a key regulator of cellular metabolism and homeostasis, controls HBP and the abundance of O-GlcNAcylation in endothelial cells via targeting GFAT1, the ratelimiting enzyme of the HBP, and that this process is a part of the proangiogenic VEGF-AMPK axis.
GFAT1 was found as an AMPK target in our systematic phosphoproteomic approach aimed at identifying novel AMPK substrates. In line with this finding two previous studies have already suggested GFAT1 as an AMPK substrate employing either purified recombinant GFAT1 in vitro [13] or recombinant GFAT1 expressed in CHO cells [12] . However, the role of AMPK-mediated GFAT1 phosphorylation in regulating GFAT activity was not clear and the biological significance of this process in a physiologically relevant system had not been investigated. Our study confirms serine 243 of GFAT1 as phosphorylation site by tandem MS and as AMPK site in a range of in vitro experiments using a recombinant GFAT1 preparation. As a novel outcome of these experiments, we show that serine 243 is a single AMPK site, which is phosphorylated to a stoichiometry of 0.33 mol/mol. In addition, we validated endogenous GFAT1 as a cellular AMPK target in WT and AMPK-null MEFs as an unequivocal model for testing AMPKdependency, thus establishing GFAT1 as a direct physiological AMPK substrate. Since we detected basal serine 243 phosphorylation of GFAT1 in AMPK-null MEFs, a second kinase such as Ca 2+ /calmodulin-dependent kinase II (CaMKII), which has recently been shown to phosphorylate GFAT at serine 243 in vitro [13] , may share this phosphorylation site with AMPK.
However, phosphorylation signals in AMPK-null MEFS were lower compared to WT MEFs suggesting that AMPK plays a major role.
Enhanced glucose fluxes through the HBP as well as increased protein O-GlcNAcylation are known to contribute to endothelial dysfunction underlying the development of diabetic vasculopathies. GFAT activity has been described in primary endothelial cells of different origin and has been shown to be upregulated by hyperglycaemia [36] . In addition, while expression of GFAT was barely detected in endothelial cells of healthy human tissues, it was increased in activated cells suggesting that it may be modulated under pathophysiological conditions [37] .
Given these indications, we addressed the role of the AMPK-GFAT1 axis in endothelial cells.
Our study demonstrates for the first time that GFAT1 is a physiological AMPK substrate in primary human endothelial cells, as VEGF, a major physiological AMPK agonist in endothelial cells, was able to increase AMPK-dependent GFAT1 phosphorylation. Using AMPK activators and AMPK-specific siRNA, we revealed an inhibitory effect of AMPK on O-GlcNAc levels, which is most likely due to inhibition of GFAT1 activity by AMPK-mediated phosphorylation, activation of recombinant GFAT1 after serine 243 phosphorylation by AMPK in vitro [13] . This discrepancy may be due to the lack of endogenous regulatory factors, e.g. allosteric regulators of angiogenesis. This in turn may contribute to cardiovascular complications in diabetes such as impaired wound healing, reduced myocardial perfusion or even organ dysfunction as observed in the islets of Langerhans (reviewed in [50, 51] ).
The interpretation of the current study is limited since the results were obtained in vitro using HUVEC as a model. Although HUVEC have been widely used to characterise endothelial functions they may differ from adult cells of different vascular beds and may be influenced by maternal and foetal factors. However, the HUVEC spheroid model has recently been characterised as a sensitive tool to study angiogenesis and provides reliable results if it is performed under standardised conditions [52] . In addition to HUVEC we have shown AMPKmediated GFAT1 phosphorylation in other cell lines (HEK293, MEFs) suggesting that this pathway is of general importance. Future experiments need to involve animal models of diabetes as well as ex vivo methodologies for evaluating endothelial cells from patients [53] . Moreover, to reveal the causal involvement of reduced O-GlcNAcylation, the respective protein targets need to be identified and the effect of mutating the sites of modification on protein function needs to be investigated. 
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